One of the major approved therapies for Alzheimer’s disease is based on a reduction of the cognitive deficits by enhancing cholinergic transmission through inhibition of acetylcholinesterase [3,4]. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.